Spinal muscular atrophy is the most common genetic killer of infants. A therapy shows promise in the clinic, but there is a potential limit to its efficacy. In this issue of Neuron, d 'Ydewalle et al. (2017) devise a new way to make it more effective.
Spinal muscular atrophy (SMA) is the most common inherited form of infant mortality. SMA is a neuromuscular disorder caused by homozygous loss-of-function mutations or deletions in the SMN1 gene, which encodes survival motor neuron (SMN) protein. Loss of SMN leads to lower motor neuron degeneration, progressive muscle weakness, paralysis, and eventually death usually due to respiratory failure within the first 2 years of life (Porensky and Burghes, 2013) . SMN is a highly conserved, ubiquitously expressed protein involved in various RNA processing pathways, including alternative splicing and mRNA localization (Gubitz et al., 2004) , underscoring an expanding role for defects in RNA metabolism in motor neuron disease.
Humans contain another gene, SMN2, which is virtually identical to SMN1, so it could serve as a backup to compensate for loss of SMN1. But, unfortunately, SMN2 has a nucleotide substitution in a segment of the gene that controls intron splicing. This single substitution is sufficient to produce a mature SMN2 mRNA that lacks exon 7 (Porensky and Burghes, 2013). Exclusion of exon 7 renders the SMN protein encoded by SMN2 highly unstable. So, frustratingly, while there is functional SMN protein available to combat the effects of SMA, because it is so unstable, it is just not able to build up to high enough levels to be able to help out (Figures 1A and 1B) .
Human genetics studies have provided further support for the notion that SMN2 could compensate for loss of SMN1 if only it was produced at sufficient levels. Copy number variations in the SMN2 gene are associated with different clinical subtypes of SMA. All humans contain at least one copy of SMN2, and the fewer copies of SMN2 you have, the more severe the clinical subtype (Porensky and Burghes, 2013) . The most common form is SMA type 1, with onset in the first few months of life, generalized muscle weakness, and an inability to sit unassisted. Children with SMA type 2 are able to sit but cannot stand or walk without assistance and are able to survive past 4 years. SMA type 3 is milder, with patients able to achieve all major motor milestones, but most need wheelchair assistance later in childhood or adulthood.
The molecular genetic description of the cause of SMA has led to the development of several promising therapeutic strategies. One approach is gene therapy based-using viral delivery to replace SMN protein. Using specific adeno-associated viral serotypes that can infect motor neurons, a one-time postnatal intravenous delivery of this virus containing SMN produced profound rescue of motor function, neuromuscular electrophysiology, and survival in a mouse model of SMA (Foust et al., 2010) . Clinical trials in human SMA patients are currently underway to test the efficacy of this gene therapy approach.
Another therapeutic strategy is to boost levels of SMN2, in order to do a better job of compensating for loss of SMN1. Antisense oligonucleotides (ASOs) are highly stable, DNA-containing synthetic nucleic acids that specifically hybridize with an mRNA target through WatsonCrick base-pairing and can trigger the enzymatic cleavage of target mRNA molecules or can manipulate pre-mRNA splicing events through steric blocking (Kole et al., 2012) . The latter type of oligonucleotide, called splice-switching oligonucleotides (SSOs), has been designed to interfere with the splicing defect that leaves out exon 7 of SMN2 (Hua et al., 2010) . These have been remarkably effective at preventing exon 7 from being excluded in the mature SMN2 mRNA and rescue disease phenotypes in SMA mice (Hua et al., 2010 (Hua et al., , 2011 . Excitingly, this approach has advanced to the clinic. In two recent clinical trials, children with SMA were administered SSOs targeting SMN2 by intrathecal injection or a sham procedure. Remarkably, in late 2016, these studies were halted because the treatment showed encouraging signs of efficacy, with the infants that received the drug showing significant improvement in motor function and meeting motor milestones compared to the children who did not receive the drug (Finkel et al., 2016) . Now, the trials have been switched to open label, and all the patients in the study can receive the oligonucleotide drug. This drug is currently moving through regulatory review and might soon become the first disease-modifying treatment for SMA.
The astonishing success of oligonucleotide therapy for SMA offers a multitude of exciting possibilities and a path forward for the treatment of this devastating disease. But there is a natural ceiling effect for this therapy, owing to the amount of starting SMN2 pre-mRNA available for targeting ( Figure 1C 
